Daclizumab (Zinbryta) approved for the treatment of multiple sclerosis (MS)

Last Updated on

May 28, 2016 – Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in young adults and occurs more frequently in women than men. For most people with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions). Over time, recovery may be incomplete, leading to progressive decline in function and increased disability. Most people experience their first symptoms of MS between the ages of 20 and 40.

The American Food & Drug Administration (FDA) has just added an additional treatment option to the armamentarium of drugs to fight MS by approving Daclizumab (Zinbryta) for the treatment of adults with relapsing forms of MS. Daclizumab (Zinbryta) is a long-acting injection that is self-administered by the

Daclizumab: A humanised therapeutic antibody against the IL-2 receptor

Daclizumab: A humanised therapeutic antibody against the IL-2 receptor

patient monthly. Daclizumab (Zinbryta) is a therapeutic humanized monoclonal antibody and works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. Previously, Daclizumab was already FDA-approved under the trade name Zenapax to prevent rejection in organ transplantation, especially in kidney transplants.

According to FDA, the effectiveness of Zinbryta was shown in two clinical trials. One trial compared Daclizumab (Zinbryta) and Avonex in 1,841 participants who were studied for 144 weeks. Patients on Daclizumab (Zinbryta) had fewer clinical relapses than patients taking Avonex. The second trial compared Daclizumab (Zinbryta) with placebo and included 412 participants who were treated for 52 weeks. In that study, patients receiving Daclizumab (Zinbryta) had fewer relapses compared to those receiving placebo.

Daclizumab (Zinbryta) comes with serious safety risks, however, and should therefore generally be used only in patients who have had an inadequate response to two or more MS drugs previously. The most serious and sometimes fatal safety risks of Daclizumab (Zinbryta) include liver injury and immune conditions. Because of these risks, Daclizumab (Zinbryta) has a boxed warning and is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS). The boxed warning tells prescribers that the drug can cause severe liver injury, including life-threatening and fatal events. Health care professionals should perform blood tests to monitor the patient’s liver function prior to starting Daclizumab (Zinbryta), monthly before each dose, and for up to six months after the last dose. The boxed warning also highlights other important risks of Zinbryta treatment including immune conditions, such as inflammation of the colon (non-infectious colitis), skin reactions, and enlargement of lymph nodes (lymphadenopathy). Additional highlighted warnings include hypersensitivity reactions (anaphylaxis or angioedema), increased risk of infections, and symptoms of depression and/or suicidal ideation.

The most common adverse reactions reported by patients receiving Daclizumab (Zinbryta) in the clinical trial that compared it to Avonex include cold symptoms (nasopharyngitis), upper respiratory tract infection, rash, influenza, dermatitis, throat (oropharyngeal) pain, eczema, and enlargement of lymph nodes. The most common adverse reactions reported by patients receiving Daclizumab (Zinbryta) when compared to placebo are depression, rash, and increased alanine aminotransferase, a fluid biomarker for disturbed liver function.

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
2 Pings/Trackbacks for "Daclizumab (Zinbryta) approved for the treatment of multiple sclerosis (MS)"

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing February 21, 2020
    A study by researchers at Mayo Clinic published this week in the Journal of Clinical Oncology suggests that all women with a breast cancer diagnosis under the age of 66 be offered germline genetic testing to determine if they have a gene mutation known to increase the risk of developing other cancers and cancers among […]
  • Cross-talk between enzymes that read and correct recipes in the cookbook of life February 21, 2020
    DNA is the hereditary material in humans, a unique cookbook of who we are. This is where you'll find the answer as to why you have your specific eye and hair colour, or perhaps why you sunburn easily.
  • Study finds certain genetic tests not useful in predicting heart disease risk February 21, 2020
    A Polygenic Risk Score—a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients—has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.
  • Major discovery in the genetics of Down syndrome February 21, 2020
    Researchers at CHU Sainte-Justine and Université de Montréal have discovered a new mechanism involved in the expression of Down syndrome, one of the main causes of intellectual disability and congenital heart defects in children. The study's findings were published today in Current Biology.
  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • Specific gut bacteria may be associated with pulmonary arterial hypertension February 24, 2020
    Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs. The unique bacterial profile predicted pulmonary arterial hypertension with 83% accuracy.
  • Intensive behavioral therapy and liraglutide 3.0 mg show positive results for weight loss February 24, 2020
    Intensive behavioral therapy (IBT) combined with liraglutide 3.0 mg (Saxenda) can produce clinically-meaningful weight loss in patients who receive the treatment in predominantly primary care settings, according to a study published online in Obesity, the flagship journal of The Obesity Society. The study is the first multi-site evaluation of the efficacy of IBT based on […]
  • Study links physical activity to quality of life in African American cancer survivors February 24, 2020
    New research published in CANCER suggests that regular exercise may improve the well-being of African American cancer survivors, but most survivors do not meet current recommendations for physical activity.
  • Obesity embargo alert for March 2020 February 24, 2020
    All print, broadcast and online journalists who receive the Obesity embargo alert agree to abide by the embargo and may not publish, post, broadcast or distribute embargoed news releases or details of the embargoed studies before the embargo date and time.
  • Could this plaque identifying toothpaste prevent a heart attack or stroke? February 24, 2020
    For decades, researchers have suggested a link between oral health and inflammatory diseases affecting the entire body -- in particular, heart attacks and strokes. Results of a randomized pilot trial of Plaque HD®, the first toothpaste that identifies plaque so that it can be removed with directed brushing, showed that it produced a statistically significant […]
Top